Connect with us

Media & Technology

Amfil Technologies Inc. (OTCMKTS: FUNN) Steady Rise Northbound as Snakes & Lattes Operator Inks Deal with MrBeast & Mr. Beast Burgers and Opens 2 New Locations

Published

on

Amfil Technologies Inc. (OTCMKTS: FUNN) soon to be renamed to Snakes & Lattes Inc. stock is northward bound moving up steadily every day on heavy accumulation as the Company makes a number of big moves. FUNN bottomed out at just under a penny after months of decline, made a serious reversal and has been northward bound since more than doubling from its lows at the beginning of January. FUNN which used to trade under the ticker AMFE has a significant international following and now that a real reversal has been established, they are busy buying back in. The stock’s recent high is $0.059 in early 2021 but long before that FUNN traded as high as $0.235 per share when the Company had just 1 or locations. As Snakes & Lattes is a physical business, the Company was hit hard by the coronavirus but has come out stronger the other side. Now with lockdowns behind us, Snakes & Lattes is doing better than ever and is in rapid expansion mode once again, opening its 8th and 9th locations just over the past 2 months alone. 

In a really big move; Snakes & Lattes signed a deal with MrBeast; one of the most successful youtubers on the platform with 92.9 million subscribers. Through a partnership with Virtual Dining Concepts (VDC) the Company plans to initially roll out Mr. Beast Burgers in 2 pilot locations, Utah and Toronto and then roll the brand to all of its locations. Mr. Beast Burgers, from Jimmy Donaldson (MrBeast), has turned into a global phenomenon overnight with over 1,000 locations in North America and Europe and immediate plans to increase the number of locations exponentially and go Worldwide. Getting MrBeast Burger into Snakes & Lattes was a big move from the Company and is expected to immediately increase revenues. Although management has not given us a projection 2022 revenues should be minimum $10 million with 9 locations open, probably much more.   

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Amfil Technologies Inc. (OTCMKTS: FUNN) is the parent company to three wholly owned subsidiaries the most exciting of which is Snakes & Lagers Inc. which holds the trade name and is the owner of Snakes & Lattes Inc. which currently operates 9 locations and growing fast. Snakes & Lattes Inc. was the first board game bar and cafe in North America, is believed to be the largest in the world and has the largest circulating public library of board games in North America for customers to choose from.  

Snakes & Lattes Inc. currently has a 100+ member staff and a strong management team including CEO Ben Castanie, Susan Lawver, Aaron McKay, Larry Leverton and Roger Mortimer. The Company recently acquired the exclusive distribution rights throughout Canada for some of the most popular board games in the world. Snakes & Lattes also operates a lucrative fulfillment and distribution division and has recently entered into the board game publishing business through the acquisition of Morning which is expected to add significant revenues to the bottom line. To this end the Company is already selling board games such as KTU/Red Panda/Pigicorn to over 192 Individual Retailers + 125 locations for retailers with multiple locations (296 total) and on Amazon USA : England : France : Germany : Italy : Canada : Saudi Arabia : Australia and Singapore.  

Microcapdaily has reported on FUNN before, back in 2018 when the stock was AMFE we wrote: The big story on AMFE is Snakes & Lagers Inc. which currently operates 3 tabletop gaming bars and cafes located in Toronto, Ontario that brought in over $7M CAD in revenue last year. The company is in the process of franchising throughout North America. 

To Find out the inside Scoop on FUNN Blockchain Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

FUNN

FUNN has been busy; just over the past 2 months Snakes & Lattes has opened 2 new locations; they acquired number 8, the Good Move Caf in Provo, Utah in March in an all-cash deal. Good Move Caf was established in 2017, at 1 E Center St Ste 100, Provo, UT 84606 near Brigham Young University. They have always been innovators; introducing game rentals, retail, and a membership program since opening. It has quickly become a hot spot for students and locals alike. Well managed and highly reviewed with over 1100 Google reviews averaging 4.6. At ~4,150 sq. ft. it is a wonderfully sized location for plenty of patrons to get their feasting and gaming on! Given the influence of the Church in the area, it will keep its namesake while operating under the Snakes & Lattes brand. Good Move Caf represents a one-off from the traditional S&L location and operates slightly different due to local culture. The Company has infused the location with elements of the Snakes & Lattes brand, such as an official retail / gift shop, rental / delivery activities and a subscription program. However, management feels it is important to recognize the values held in this region and such differences mean keeping the local name. It is clearly a successful business and a great opportunity to expand the Company’s North American footprint. 

In April the Company acquired its 9th location; Gamehaus in Glendale, California via ownership of the outstanding SBA loan. Gamehaus was established in 2013 by Rob Cron and Terry Chiu. Located near Hollywood at 1800 South Brand Blvd., #107 Glendale, CA. The Gamehaus already has an established game library of over 1400 titles. FUNN Management plans to further increase capacity from current 100 seats by expanding and turning the adjacent space into retail space have started. This marks the Company’s first location in the state of California. The location will stay open during the transition with the rebrand launch coming this summer along with a local social media campaign. 

This Ninth location represents another conversion out of many FUNN Management is exploring across the United States and Canada. Opportunities continue to come in with one-off locations proactively reaching out to consider a conversion to the Snakes brand. When management finds a caf that meets its requirements for; size, market potential, location relative to the Snakes & Lagers brand demographics, financially sound post due diligence, and ease of transition management begins the deep dive review process. These conversions are a separate list from the USA expansion team efforts and represent another stream for corporate growth. More information on the USA expansion team to come! With its first true West Coast location, FUNN Management is excited to continue its plan to have Snakes & Lattes brand locations coast to coast in North America. 

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $14 million market valuation FUNN has 757,486,406 shares outstanding and is capped there as AS is set at 800 million. While the stock price has been decimated in recent years, the Company has come out of the pandemic stronger than ever with all of its locations re opened and already in rapid expansion mode once again, opening locations number 8th and 9th just over the past 2 months alone. FUNN stock is moving steady northbound with power and this is a stock with a history of big moves with runner in its blood skyrocketing to $0.235 per share back in 2017 when the Company had just 1 location. Now with the pandemic behind it and all 9 locations of Snakes & Lattes operating at full throttle, the expansion team working hard securing new locations, FUNN significant international following is heavily accumulating and looking back at the stocks previous highs of $0.235 per share. At a $14 million total market valuation, location #10 coming any day and a new deal with Mr. Beast Burgers, FUNN has a lot of catalysts in place, ready liquidity, momentum and a lot of room to grow fast.   Currently investors are awaiting audited financials and a possible up listing. We will be updating on FUNN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with FUNN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in FUNN either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Featured

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership

Published

on

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan's proprietary target discovery platform.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable. 

The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. 

Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand: 

Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.

As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.

To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.

Here are a couple of blurbs from the management team

“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”

“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”

What’s retail saying?

As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. 

Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day.  Compared to the ~27M shares traded at the time of writing, that’s a massive shift.

We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

ContraFect Corp (NASDAQ: CFRX): A Low Float Runner

Published

on

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual.

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.

However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.

To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Summary of latest PR on April 26, 2023

ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.

What are retail traders saying?

https://twitter.com/RealWillTopol/status/1651553835801001986?s=20

It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them. 

We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits. 

However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.

About ContraFect Corp (NASDAQ: CFRX)

ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.

We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sasin Tipchai from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.